Timothy P. Thomas

Array ( [id] => 17739697 [patent_doc_number] => 20220225159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => PARENTERAL DELIVERY OF AVIZAFONE [patent_app_type] => utility [patent_app_number] => 17/707830 [patent_app_country] => US [patent_app_date] => 2022-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3498 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17707830 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17718955 [patent_doc_number] => 20220211674 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => Thromboxane Receptor Antagonists in AERD/Asthma [patent_app_type] => utility [patent_app_number] => 17/705522 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733213 [patent_doc_number] => 20220218672 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => Thromboxane Receptor Antagonists in AERD/Asthma [patent_app_type] => utility [patent_app_number] => 17/705557 [patent_app_country] => US [patent_app_date] => 2022-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8406 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18018956 [patent_doc_number] => 20220370455 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => TOPICAL FORMULATION FOR A JAK INHIBITOR [patent_app_type] => utility [patent_app_number] => 17/704155 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17704155 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19716082 [patent_doc_number] => 12201597 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Specialized pro-resolving mediators (SPMs) as melanocyte growth promoter and pro-survival factors and uses thereof [patent_app_type] => utility [patent_app_number] => 18/026765 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 13819 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19716082 [patent_doc_number] => 12201597 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Specialized pro-resolving mediators (SPMs) as melanocyte growth promoter and pro-survival factors and uses thereof [patent_app_type] => utility [patent_app_number] => 18/026765 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 13819 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19716082 [patent_doc_number] => 12201597 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Specialized pro-resolving mediators (SPMs) as melanocyte growth promoter and pro-survival factors and uses thereof [patent_app_type] => utility [patent_app_number] => 18/026765 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 13819 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19716082 [patent_doc_number] => 12201597 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => Specialized pro-resolving mediators (SPMs) as melanocyte growth promoter and pro-survival factors and uses thereof [patent_app_type] => utility [patent_app_number] => 18/026765 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 13819 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18026765 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17718972 [patent_doc_number] => 20220211691 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => TREATMENT OF DRY EYE DISEASE [patent_app_type] => utility [patent_app_number] => 17/654969 [patent_app_country] => US [patent_app_date] => 2022-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17654969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19629637 [patent_doc_number] => 20240408086 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-12 [patent_title] => USE OF LUVADAXISTAT FOR THE TREATMENT OF COGNITIVE IMPAIRMENT [patent_app_type] => utility [patent_app_number] => 18/548469 [patent_app_country] => US [patent_app_date] => 2022-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -66 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18548469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17958568 [patent_doc_number] => 20220339148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-27 [patent_title] => MULTI-KINASE INHIBITORS OF VEGF AND TGF BETA AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/667909 [patent_app_country] => US [patent_app_date] => 2022-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17667909 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18325996 [patent_doc_number] => 20230124124 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-20 [patent_title] => COMPOSITIONS AND METHODS FOR MYOPIA CONTROL AND ORTHOKERATOLOGY LENSES TREATMENT [patent_app_type] => utility [patent_app_number] => 17/668106 [patent_app_country] => US [patent_app_date] => 2022-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17668106 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609766 [patent_doc_number] => 20220152045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => DOSING REGIMEN OF SEDATIVE [patent_app_type] => utility [patent_app_number] => 17/665662 [patent_app_country] => US [patent_app_date] => 2022-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17665662 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609684 [patent_doc_number] => 20220151963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => PARENTERAL DELIVERY OF AVIZAFONE [patent_app_type] => utility [patent_app_number] => 17/590402 [patent_app_country] => US [patent_app_date] => 2022-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3475 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17590402 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17609702 [patent_doc_number] => 20220151981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-19 [patent_title] => USE OF CANNABINOIDS AND TERPENES FOR TREATMENT OF ORGANOPHOSPHATE AND CARBAMATE TOXICITY [patent_app_type] => utility [patent_app_number] => 17/589012 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17589012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865273 [patent_doc_number] => 20220288008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => JUICE BEVERAGE FOR PREVENTION AND TREATMENT OF RENAL STONES [patent_app_type] => utility [patent_app_number] => 17/588693 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865273 [patent_doc_number] => 20220288008 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => JUICE BEVERAGE FOR PREVENTION AND TREATMENT OF RENAL STONES [patent_app_type] => utility [patent_app_number] => 17/588693 [patent_app_country] => US [patent_app_date] => 2022-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17588693 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19140329 [patent_doc_number] => 20240139105 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-02 [patent_title] => PHARMACEUTICAL COMPOSITION CONTAINING GHRP-6 [patent_app_type] => utility [patent_app_number] => 18/274955 [patent_app_country] => US [patent_app_date] => 2022-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8099 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18274955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18328261 [patent_doc_number] => 11633478 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-25 [patent_title] => Compositions and kits for Omeprazole suspension [patent_app_type] => utility [patent_app_number] => 17/576496 [patent_app_country] => US [patent_app_date] => 2022-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 40229 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17576496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17519270 [patent_doc_number] => 20220105118 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/553456 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33360 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553456 [rel_patent_id] =>[rel_patent_doc_number] =>)